Leerink Partners Starts Protagonist Therapeutics (PTGX) at Outperform
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Leerink Partners initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Outperform rating and a price target of $17.00.
Analyst Joseph Schwartz commented, "Protagonist is aiming to become the standard of care therapy for moderate to severe Irritable Bowel Disease (IBD) patients, a large and growing market opportunity. Currently approved therapies are insufficient, with upwards of 50% of moderate and severe IBD patients failing to achieve a sustained response to currently available treatments. Herein we discuss PTGX's currently planned clinical programs along with our perceived strengths and outstanding questions."
Shares of Protagonist Therapeutics closed at $12.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- UPDATE: Oppenheimer Downgrades Williams-Sonoma (WSM) to Perform
- Edwards Lifesciences (EW) PT Lowered to $114 at Stifel, 'Buy' Kept
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!